Skip to main content

Table 4 Adherence to heart failure treatment guidelines (ESC Guidelines), GPs=general practitioners

From: Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation

Case number Treatment guidelines issue Clinical pharmacist recommendations GPs acceptance (YES/NO)
1. Methyldigoxin treatment Methyldigoxin discontinuation and perindopril initiation YES
2. Methyldigoxin treatment Methyldigoxin discontinuation and enalapril initiation NO
3. Methyldigoxin treatment + β-blocker +ACE inhibitor Methyldigoxin treatment discontinuation YES
4. Methyldigoxin treatment +ACE inhibitor Methyldigoxin treatment discontinuation + β-blocker initiation YES
5. Methyldigoxin treatment β-blocker initiation and ACE inhibitor initiation NO
6, 7, 8, 9, 10. Methyldigoxin treatment + β-blocker Methyldigoxin treatment discontinuation YES, NO, YES, NO, YES
11. Methyldigoxin treatment +ACE inhibitor Methyldigoxin treatment discontinuation + β-blocker initiation NO
12. 1.25 mg bisoprolol daily Drug adjustment (2,5 mg daily) YES
13, 14, 15. ACE inhibitor treatment β-blocker adding NO, NO, NO
16, 17, 18. ACE inhibitor treatment with verapamil Verapamil discontinuation and selective β-blocker initiation NO, NO, NO
19. Inappropriate dosing of ACE inhibitor and β-blocker Reduce the ACE inhibitor dose and increase the dose of the β-blocker NO
20. Nonselective β-blocker Switching to bisoprolol NO, YES
21. Amlodipine treatment Amlodipine discontinuation and β-blocker (bisoprolol) initiation YES
  1. Interventions where CP's recommendations were accepted are presented in a bold form